Novartis AG logo

NOVN - Novartis AG News Story

CHF79.49 0.4  0.5%

Last Trade - 4:37pm

Sector
Healthcare
Size
Large Cap
Market Cap £140.98bn
Enterprise Value £165.31bn
Revenue £35.93bn
Position in Universe 4th / 1051

CureVac starts review process in Switzerland for COVID-19 vaccine hopeful

Mon 19th April, 2021 12:45pm
ZURICH, April 19 (Reuters) - Germany's CureVac  5CV.DE 
filed in Switzerland for a rolling review of its COVID-19
vaccine candidate, the Swiss drugs regulator Swissmedic said on
Monday, as yet another maker of shots races toward the approval
finish line.
    Switzerland, which to date has approved COVID-19 shots from
Pfizer  PFE.N , Moderna  MRNA.O  and Johnson & Johnson  JNJ.N ,
has placed orders for five million doses of CureVac's vaccine.
It is a so-called mRNA vaccine, like those from Moderna and
Pfizer that are already on the market.
    Such rolling reviews are designed to streamline the approval
process, with companies submitting data and information as it
comes in to Swissmedic. It's unclear how long the review will
take, Swissmedic said, adding that hinges largely on CureVac.
 urn:newsml:reuters.com:*:nL8N2LL5T5
    "The duration of the rolling review will depend on the
completeness of the data submitted by CureVac and the results of
the clinical trials, and cannot therefore be predicted,"
Swissmedic said.
    Although AstraZeneca  AZN.L  was the first company to start
the review process in Switzerland in early October for its
vaccine, regulators have said they still don't have enough
information to make a decision on the British company's shot's
approval. 
    Swiss drugmaker Novartis  NOVN.S  has agreed to help make
CureVac's vaccine at a plant in Austria. The German company is
aiming to release pivotal data from its clinical trial on the
efficacy of its candidate early in the second quarter.
 urn:newsml:reuters.com:*:nL5N2L24OE
    

 (Reporting by John Miller, editing by Louise Heavens)
 ((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters
Messaging: j.miller.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.